Dr. Reddy's Laboratories reported Q2 FY27 net profit of ₹2,894 Cr on revenue of ₹19,704 Cr, with profit down -9.2% year-on-year and short of street estimates. The stock fell in reaction as investors weighed the margin trend and management's outlook for the rest of the year.
Last 8 quarters / 3 years
| Period | Revenue | Net Profit | EPS | YoY | QoQ |
|---|---|---|---|---|---|
| Q3 FY25 | ₹15,971 Cr | ₹2,351 Cr | ₹28.34 | — | — |
| Q4 FY25 | ₹16,625 Cr | ₹2,664 Cr | ₹32.12 | — | +13.3% |
| Q1 FY26 | ₹17,122 Cr | ₹2,692 Cr | ₹32.46 | — | +1.0% |
| Q2 FY26 | ₹17,651 Cr | ₹3,187 Cr | ₹38.42 | — | +18.4% |
| Q3 FY26 | ₹18,816 Cr | ₹3,026 Cr | ₹36.48 | +28.7% | -5.1% |
| Q4 FY26 | ₹18,519 Cr | ₹2,814 Cr | ₹33.92 | +5.6% | -7.0% |
| Q1 FY27 | ₹18,216 Cr | ₹2,596 Cr | ₹31.30 | -3.6% | -7.7% |
| Q2 FY27 | ₹19,704 Cr | ₹2,894 Cr | ₹34.89 | -9.2% | +11.5% |
Last 4 quarters
Dr. Reddy's Laboratories announced an interim dividend, with the record date set for later this month. The payout is consistent with the company's stated capital-return policy.
Several brokerages maintained a positive stance on Dr. Reddy's Laboratories, citing improving return ratios and a clearer growth runway, while a few flagged valuations as the key risk.
Dr. Reddy's Laboratories reported revenue and profit broadly in line with Street expectations, with management flagging stable demand and a healthy order pipeline into the second half.
In an exchange filing, Dr. Reddy's Laboratories said its board cleared a multi-year investment to expand capacity, aimed at meeting demand and improving operating leverage over the medium term.
Dr. Reddy's Laboratories reported revenue and profit broadly in line with Street expectations, with management flagging stable demand and a healthy order pipeline into the second half.
Dr. Reddy's Laboratories entered a strategic partnership to widen its addressable market. Management expects the tie-up to contribute modestly to revenue over the next few quarters.
Tap a metric label to learn what it means.
Pharmaceuticals
| Company | P/E | 1Y |
|---|---|---|
| Sun Pharmaceutical ₹4,27,000 Cr | 48.5 | +36.2% |
| Cipla ₹1,23,000 Cr | 47.7 | +6.9% |
| Divi's Laboratories ₹1,57,000 Cr | 39.8 | +7.0% |
| Apollo Hospitals ₹99,000 Cr | 40.8 | +25.2% |
Dr. Reddy's Laboratories is a leading Indian company in the pharmaceuticals space within the Healthcare sector. It is a constituent of the Nifty 50 and is actively tracked by institutional and retail investors.